PMID- 22212569
OWN - NLM
STAT- MEDLINE
DCOM- 20120515
LR  - 20181201
IS  - 1478-3231 (Electronic)
IS  - 1478-3223 (Linking)
VI  - 32 Suppl 1
DP  - 2012 Feb
TI  - Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety 
      management in clinical practice.
PG  - 32-8
LID - 10.1111/j.1478-3231.2011.02707.x [doi]
AB  - Effective management of adverse events (AEs) is important to prevent treatment 
      discontinuation and optimize hepatitis C virus infection eradication rates. The 
      addition of direct-acting antiviral agents, telaprevir (TVR) or boceprevir to 
      pegylated interferon (PEG-IFN) and ribavirin (RBV) represents a new era of 
      therapy associated with an improvement in treatment response rates and an 
      impairment of the safety profile compared to PEG-IFN/RBV. An increase in the 
      frequency and severity of anaemia was reported in clinical trials for both drugs, 
      and skin disorders including rash and pruritus occurred more frequently with the 
      TVR-based regimen. These AEs are generally manageable and do not lead to early 
      discontinuation. The management of anaemia has not been clearly established, and 
      the impact of RBV dose reductions and erythropoietin alpha use on treatment 
      efficacy and safety must be clarified. The management of rashes, which were mild 
      and moderate in more than 90% of the cases, is well planned, does not require TVR 
      discontinuation and can be treated using emollients and topical corticosteroids. 
      However, approximately 5% of rashes were severe, and a few cases were classified 
      as severe cutaneous adverse reactions leading to treatment discontinuation.
CI  - (c) 2012 John Wiley & Sons A/S.
FAU - Hezode, Christophe
AU  - Hezode C
AD  - Department of Hepatology and Gastroenterology, Hopital Henri Mondor, Universite 
      Paris-Est, Creteil, France. christophe.hezode@hmn.aphp.fr
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Liver Int
JT  - Liver international : official journal of the International Association for the 
      Study of the Liver
JID - 101160857
RN  - 0 (Antiviral Agents)
RN  - 0 (Interferon-alpha)
RN  - 0 (Oligopeptides)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Serine Proteinase Inhibitors)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 49717AWG6K (Ribavirin)
RN  - 655M5O3W0U (telaprevir)
RN  - 89BT58KELH 
      (N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide)
RN  - 9DLQ4CIU6V (Proline)
RN  - Q46947FE7K (peginterferon alfa-2a)
SB  - IM
MH  - Anemia/chemically induced/therapy
MH  - Antiviral Agents/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Hepatitis C, Chronic/*drug therapy
MH  - Humans
MH  - Interferon-alpha/therapeutic use
MH  - Oligopeptides/adverse effects/*therapeutic use
MH  - Polyethylene Glycols/therapeutic use
MH  - Proline/adverse effects/*analogs & derivatives/therapeutic use
MH  - Recombinant Proteins/therapeutic use
MH  - Ribavirin/therapeutic use
MH  - Serine Proteinase Inhibitors/adverse effects/*therapeutic use
MH  - Skin Diseases/chemically induced
MH  - Withholding Treatment
EDAT- 2012/01/11 06:00
MHDA- 2012/05/16 06:00
CRDT- 2012/01/04 06:00
PHST- 2012/01/04 06:00 [entrez]
PHST- 2012/01/11 06:00 [pubmed]
PHST- 2012/05/16 06:00 [medline]
AID - 10.1111/j.1478-3231.2011.02707.x [doi]
PST - ppublish
SO  - Liver Int. 2012 Feb;32 Suppl 1:32-8. doi: 10.1111/j.1478-3231.2011.02707.x.